Navigation Links
Investigational anti-restenosis drug pimecrolimus disappoints
Date:3/31/2008

o designed to a novel stent design featuring reservoirs that are filled individually with an active drug and resorbable polymer matrix. This design enables the stent to deliver more than one drug at a time from adjacent reservoirs. In the case of the GENESIS study, the SymBio stent was loaded with two medications that inhibit restenosis by two different pathways. In addition, the reservoirs limit the contact between the polymer and the artery wall.

For the study, Dr. Verheye and his colleagues enrolled 248 patients with single new coronary artery lesions, recruiting them from 18 medical centers in Europe and Israel. Patients were randomly assigned to stenting with the Corio stent, which delivers pimecrolimus; the SymBio stent, which delivers both pimecrolimus and paclitaxel; or the paclitaxel-coated CoStar stent. All of these stents are made with the reservoir design.

After nearly six months of follow-up, shrinkage of the arterial opening inside the stent (in-stent late loss) was greatest with the pimecrolimus-eluting Corio stent (1.40 mm), mid-range with the dual-drug SymBio stent (0.96 mm) and least with the paclitaxel-eluting CoStar stent (0.58 mm), but none of the differences between stents was statistically significant. Other angiographic findings followed the same pattern, including minimal lumen diameter, percent diameter stenosis and restenosis rateas did the findings of intravascular ultrasound at six months.

At six months, 39 percent of patients treated with the Corio stent experienced a major adverse cardiac event (MACE), including a 35 percent rate of repeat procedure in the target artery. With the SymBio stent, those rates were both 14.4 percent, and with the CoStar stent, they were both 2.0 percent. The difference in MACE rates between the CoStar stent and both of the pimecrolimus stents was highly statistically significant (p<0.0001). The rate of stent thrombosis at six months was 2.0 percent with the Corio stent, 1.0 per
'/>"/>

Contact: Kathy Boyd David
pr@scai.org
717-422-1181
Weber Shandwick Worldwide
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Investigational drug tested for preventing muscle fiber death in muscular dystrophy
2. Enrollment completed in 2 pivotal phase III studies of the investigational cancer drug vandetanib
3. New Drug Application Submitted to FDA for Investigational Analgesic Tapentadol Immediate Release Tablets
4. UCB Announces Positive Results From Phase II Clinical Trial of Investigational Anti-Epilepsy Drug Brivaracetam
5. SGX Pharmaceuticals Submits Investigational New Drug Application for SGX523, a Highly Potent, Selective, Orally Bioavailable cMET Inhibitor
6. MetaCure(TM) Launches Investigational Study of Gastric Stimulator for Patients With Type 2 Diabetes Who are Overweight
7. Abbotts Investigational SIMCOR(R) Offers Comparable LDL Lowering to Simvastatin and Significantly Raises HDL and Lowers Triglycerides in Phase III Study
8. Dynavax and Merck & Co., Inc. Announce Partnership to Develop HEPLISAV(TM), an Investigational Hepatitis B Vaccine Currently in Phase 3
9. Ono and Medarex Announce Allowance of Investigational New Drug Application for Fully Human Anti-PD1 Antibody
10. Supratek Pharma Inc. announced today that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for SP1049C for the treatment of metastatic adenocarcinoma of the upper gastrointestinal tract
11. Accentia announces investigational new drug application for Revimmune for refractory MS
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/3/2015)... ... September 03, 2015 , ... “Love in Tokyo” an independent romantic comedy ... and Amazon and will be released on DVD early next year, by ... Foreigner,” Itsuka, an actress and singer/songwriter, and Jason London, lead from “Dazed and Confused.” ...
(Date:9/3/2015)... ... September 03, 2015 , ... ... will be participating at the highly anticipated Mississippi Gulf Babypalooza on September 19, ... from all over, from Gulfport, Biloxi, and beyond. We will be discussing setting ...
(Date:9/3/2015)... ... ... At Renew Man™, we have seen an increasing number of our clients ... primary care physician dictates and the patient obeys. Instead, our clients are members of ... and empowered to choose their own treatment options. , Recognizing that many men may ...
(Date:9/3/2015)... ... September 03, 2015 , ... About 220,800 new cases of prostate cancer are reported each year, ... diagnosed with prostate cancer during their lifetime. While only one man in 10,000 will typically ... by age 65, according to the American Cancer Society. , Prostate ...
(Date:9/3/2015)... ... ... James Earl Jones will be hosting an upcoming VOICES IN AMERICA segment that highlights ... segment that discusses why it is important for the workplace to be healthier, the ... working environment. , Employers are out billions of dollars year after year due to ...
Breaking Medicine News(10 mins):Health News:The Romantic Comedy Film "Love in Tokyo" Has Been Released on ITunes, Google Play, and Amazon 2Health News:State Farm Agent EJ Roberts to Help Expecting Mothers at the Mississippi Gulf Babypalooza 2Health News:Men Dissatisfied with the Primary Care Physician’s Approach to Andropause Are Turning to Renew Man™ 2Health News:Men Dissatisfied with the Primary Care Physician’s Approach to Andropause Are Turning to Renew Man™ 3Health News:Noted Santa Rosa Urologist Dr. Michael Lazar Provides Insights on Prostate Cancer Treatments in Recognition of Prostate Cancer Awareness Month 2Health News:Noted Santa Rosa Urologist Dr. Michael Lazar Provides Insights on Prostate Cancer Treatments in Recognition of Prostate Cancer Awareness Month 3Health News:James Earl Jones Hosts a New "Voices In America" Piece on Making the Workplace Healthier 2
... Ireland Cancer Center of University Hospitals Case Medical Center, in ... the Cancer Research Network, found that the majority of older ... the standard of treatment five years of daily oral ... the February issue of Journal of Clinical Oncology and released ...
... from fentanyl-laden patches , , , FRIDAY, Dec. 21 (HealthDay ... health officials are warning of reports of deaths and dangerous ... are prescribed to treat chronic pain. , The patches deliver ... primarily used by cancer patients who are tolerant to the ...
... Founder and CEO Dennis Gillings, Bain ... ... Quintiles,Transnational Corp. today announced the formation of a new investor,partnership to ... CEO Dennis Gillings, CBE, and the management team.,Gillings and global private ...
... Highlights include generic drug use, diagnostic imaging, ... to improve the quality and efficiency of care ... support for diagnostic,imaging which HealthPartners introduced in February, ... program provides physicians the latest,guidelines from the American ...
... NEWPORT BEACH, Calif., Dec. 21 When men leave ... of care and,treatment. More often than not, a spouse ... often lacks the information and confidence,necessary to provide all ... being under more stress than the patient., Laurel ...
... from 3 to 4 per day after service was added ... -- Simply adding a salad bar to the school lunch ... vegetables, U.S. researchers say. , The University of California, Los ... at three L.A. area schools. The children were interviewed before ...
Cached Medicine News:Health News:Ireland Cancer Center researcher finds standard treatment for breast cancer not followed 2Health News:FDA Renews Warnings on Pain-Relief Patch 2Health News:FDA Renews Warnings on Pain-Relief Patch 3Health News:FDA Renews Warnings on Pain-Relief Patch 4Health News:Quintiles Transnational Forms New Ownership Team with Current Investors Gillings, TPG and Temasek Joined by Bain Capital and 3i 2Health News:Quintiles Transnational Forms New Ownership Team with Current Investors Gillings, TPG and Temasek Joined by Bain Capital and 3i 3Health News:Quintiles Transnational Forms New Ownership Team with Current Investors Gillings, TPG and Temasek Joined by Bain Capital and 3i 4Health News:HealthPartners Reports 2007 Most Cost Effective Programs Reduce Expenses by $74 Million 2Health News:Helping Couples Fight Prostate Cancer, This Week on Your Cancer Today(TM) 2Health News:School Salad Bar Boosts Kids' Fruit, Veggie Intake 2
(Date:9/2/2015)... , Sept. 2, 2015 Research and ... of the "An Introduction to Medical Device ... 2-3, 2015)" conference to their offering. ... introduction to the regulations and requirements that apply ... highly interactive, using real life examples and state-of- ...
(Date:9/2/2015)... 2, 2015  Research and Markets ( http://www.researchandmarkets.com/research/rf2c5p/an_introduction ... "An Introduction to the Medical Devices Directive (London, ... their offering. This seminar provides ... legislation. It will explain the Directives and which ... how to choose one and outline what a ...
(Date:9/2/2015)... 2, 2015 Research and Markets ( http://www.researchandmarkets.com/research/6x789c/new_eu ... EU Pharmacovigilance Legislation (London, UK - November 16-17, 2015)" ... 15 new EU modules concerning Pharmacovigilance are a major ... in Europe . The intention of ... their requirements, examine how they overlap and fit together ...
Breaking Medicine Technology:An Introduction to Medical Device Software: Regulations and Requirements Course - London, UK - November 2-3, 2015 2
... Reportlinker.com announces that a new market research ... Rheumatoid Arthritis Market Forecast ... novel oral drugs and reformulations of current brands ... major markets, rising from $12bn in 2010 to ...
... 2011 Reportlinker.com announces that a ... in its catalogue: ... - Pipeline Assessment and Market Forecasts ... http://www.reportlinker.com/p0617091/Post-Menopausal-Hormone-Replacement-Therapy-HRT---Pipeline-Assessment-and-Market-Forecasts-to-2018.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Therapy Post-Menopausal ...
Cached Medicine Technology:Rheumatoid Arthritis Market Forecast 2Post-Menopausal Hormone Replacement Therapy (HRT) - Pipeline Assessment and Market Forecasts to 2018 2Post-Menopausal Hormone Replacement Therapy (HRT) - Pipeline Assessment and Market Forecasts to 2018 3Post-Menopausal Hormone Replacement Therapy (HRT) - Pipeline Assessment and Market Forecasts to 2018 4Post-Menopausal Hormone Replacement Therapy (HRT) - Pipeline Assessment and Market Forecasts to 2018 5Post-Menopausal Hormone Replacement Therapy (HRT) - Pipeline Assessment and Market Forecasts to 2018 6Post-Menopausal Hormone Replacement Therapy (HRT) - Pipeline Assessment and Market Forecasts to 2018 7Post-Menopausal Hormone Replacement Therapy (HRT) - Pipeline Assessment and Market Forecasts to 2018 8Post-Menopausal Hormone Replacement Therapy (HRT) - Pipeline Assessment and Market Forecasts to 2018 9
... Welch Allyn Frequency Doubling Technology. It ... field testing by combining early glaucoma ... and basic glaucoma management tools., ,Like ... doubles as an in-office glaucoma screener ...
... The Rapidlab 1200's speed and ... critical decisions in a timely manner ... will value, especially patients. In fact, ... all parameters in just one minute. ...
Erbium Laser with Sapphire Erbium Handpiece for Dermatological and Cosmetic Surgery...
... Utilizing process automation, robust ... and EMR/Practice Management), and rules-based ... issues, improves efficiency, reduces errors, ... of Harvest LIS includes many ...
Medicine Products: